Progress and shortcomings in European national strategic plans for pandemic influenza.

OBJECTIVE To repeat and update our previous evaluation (2005) of Europe's national pandemic influenza preparedness plans and assess the progress that has been made. METHODS We assessed published national pandemic influenza preparedness plans from the European Union countries, from the two acceding countries (Bulgaria and Romania) and from Norway, Switzerland and Turkey. Plans were eligible for inclusion if formally published before 30 September 2006. We referred to WHO guidelines and used a systematically applied data extraction form. We considered plans in relation to border control measures, antiviral drugs and vaccines. FINDINGS Twenty-nine countries had plans that were included in the analysis, compared with 21 countries in 2005. Substantial differences existed in countries' plans for border control measures, and many plans diverged from WHO guidelines. Likewise, countries' plans on antiviral drugs and vaccines varied and operational planning remained weak. CONCLUSION Although progress has been made in the completeness of plans, problems remain unsolved regarding national plans' divergence from international recommendations, persisting strategic incoherence and operational limitations in relation to potentially scarce resources. Border control plans also show gaps and inconsistencies, and these are likely to be politically volatile during a pandemic.

[1]  K. Subbarao,et al.  Can Immunity Induced by the Human Influenza Virus N1 Neuraminidase Provide Some Protection from Avian Influenza H5N1 Viruses? , 2007, PLoS Medicine.

[2]  J. Brownstein,et al.  Empirical Evidence for the Effect of Airline Travel on Inter-Regional Influenza Spread in the United States , 2006, PLoS medicine.

[3]  Stefania Salmaso,et al.  How prepared is Europe for pandemic influenza? , 2006, The Lancet.

[4]  Sandra Mounier-Jack,et al.  Pandemic influenza preparedness in the Asia–Pacific region , 2006, The Lancet.

[5]  Keiji Fukuda,et al.  Nonpharmaceutical Interventions for Pandemic Influenza, International Measures , 2006, Emerging infectious diseases.

[6]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[7]  K. Nichol,et al.  Influenza vaccination: policy versus evidence , 2006, BMJ : British Medical Journal.

[8]  A. Nicoll,et al.  Limitations of recently published review of national influenza pandemic plans in Europe. , 2006, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[9]  B. Murphy,et al.  Live, Attenuated Influenza A H5N1 Candidate Vaccines Provide Broad Cross-Protection in Mice and Ferrets , 2006, PLoS medicine.

[10]  D. Fidler Germs, governance, and global public health in the wake of SARS. , 2004, The Journal of clinical investigation.

[11]  T. Jefferson,et al.  Amantadine and rimantadine for influenza A in adults. , 2006, The Cochrane database of systematic reviews.

[12]  D. Fidler,et al.  Avian and pandemic influenza: Progress and problems with global health governance , 2007, Global public health.

[13]  S. Mounier-Jack,et al.  How prepared is Europe for pandemic infl uenza , 2006 .

[14]  A. Hatzakis,et al.  Role of combination antiviral therapy in pandemic influenza and stockpiling implications , 2007, BMJ : British Medical Journal.

[15]  Sandra Mounier-Jack,et al.  How prepared is Europe for pandemic influenza? Analysis of national plans , 2006, The Lancet.